Skip to Main content Skip to Navigation
Journal articles

Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives.

Abstract : BACKGROUND: Median survival of metastatic malignant melanoma is 6.0 to 7.5 months, with a 5-year survival of approximately 6.0%. Although long-term complete remissions are rare, few reports describe cases after chemotherapy. Fifty-three patients with metastatic melanoma were treated with Cystemustine, a chloroethyl nitrosourea (CENU) (60 or 90 mg/m2). CASE PRESENTATION: We describe 5 cases, presenting with complete response with long-term disease-free survival of long-term remission of 14, 12, 9, 7 and 6 years after Cystemustine therapy alone. CONCLUSION: Long-term survival has already been described in literature, but in all cases they have been obtained after chemotherapy associated with or followed by surgery. But despite these noteworthy and encouraging but also rare results, it appears essential to increase Cystemustine efficiency.
Document type :
Journal articles
Complete list of metadatas

Cited literature [2 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00089310
Contributor : Delphine Autard <>
Submitted on : Thursday, August 17, 2006 - 11:43:14 AM
Last modification on : Thursday, June 11, 2020 - 3:19:32 AM
Long-term archiving on: : Tuesday, September 18, 2012 - 4:43:01 PM

Identifiers

Collections

Citation

Xavier Durando, Emilie Thivat, Michel d'Incan, Anne Sinsard, Jean-Claude Madelmont, et al.. Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives.. BMC Cancer, BioMed Central, 2005, 5, pp.147. ⟨10.1186/1471-2407-5-147⟩. ⟨inserm-00089310⟩

Share

Metrics

Record views

470

Files downloads

711